David Darling has a dig at DHB delays

David Darling has a dig at DHB delays
David Darling: Disappointed with slow adoption (Image: Supplied)
Brent Melville
Pacific Edge’s cancer diagnostic products have made headway into the US healthcare sector over the past several years, but many New Zealand patients continue to be shut out by the bureaucracy of local DHBs, the company says.Last June, the NZX-listed firm announced giant US healthcare group Kaiser Permanente had approved its Cxbladder products for use by urologists to monitor patients for bladder cancer. A month later it announced Cxbladder tests will be covered by the Centers for Medicare and Medicaid Services (CMS) across the US mar...

More Markets

NZX flat after Vital announcement
Markets

NZX flat after Vital announcement

The NZX was flat, but property stocks declined more than 1%.

Economic hedges help ANZ NZ lift annual profit
Finance

Economic hedges help ANZ NZ lift annual profit

ANZ NZ styles its full-year results as solid as net-interest margin nudges higher.

PaySauce shares rise as it eyes Australia
Markets

PaySauce shares rise as it eyes Australia

Customer numbers for micro and rural payroll firm increased 9% for six months to Sept 30.

Vital Healthcare taking property portfolio management in-house
Markets

Vital Healthcare taking property portfolio management in-house

UPDATED: 'Relatively welcome' – NZSA on Vital's $220m plan.